The process begins within the brainstem, specifically in the trigeminal nucleus caudalis. This nucleus receives signals from the trigeminal nerve, which innervates the cranial blood vessels and meninges (the brain’s protective coverings). In a susceptible brain, various triggers activate this trigeminovascular system, leading to the release of vasoactive neuropeptides like Calcitonin Gene-Related Peptide (CGRP) and Substance P.
In addition to managing symptoms, there are several prevention strategies that can help reduce the frequency of episodic migraines. Some common prevention strategies include: what are episodic migraines
Doctors often ask patients to keep a . This is vital because most people underestimate their headache frequency once they are in the doctor's office. Tracking helps identify if the episodic migraines are becoming more frequent, which is a warning sign of transition to chronic migraine. The process begins within the brainstem, specifically in
This is indicated when attacks occur four or more times per month, or when acute medications are ineffective or overused. Traditional oral preventives include beta-blockers (propranolol), anticonvulsants (topiramate, valproate), tricyclic antidepressants (amitriptyline), and candesartan. A revolutionary advance has been the development of monoclonal antibodies targeting CGRP or its receptor (e.g., erenumab, galcanezumab). These injectable or intravenous drugs are specifically designed for migraine prevention and can reduce attack frequency by 50% or more in a substantial proportion of patients with EM. In addition to managing symptoms, there are several
Fortunately, there are several treatment options available to help manage episodic migraines. These include:
One of the most misunderstood aspects of episodic migraine is that the "headache" is only one part of the timeline. A full migraine attack can last anywhere from 4 to 72 hours and occurs in distinct phases: